-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the context of the current changeable pharmaceutical market, global pharmaceutical companies are accelerating the adjustment of talent, product structure and organizational structure according to market development trends and their own needs
However, layoffs are a result, a means rather than a cause.
In April, 16 companies (as of the 28th)
In April, 16 companies (as of the 28th)April 27, Solid Biosciences : The company announced a strategic realignment and restructuring to adjust the development of Duchenne muscular dystrophy drugs SGT-001 and SGT-003 to the highest priority
April 27, Solid Biosciences
April 25, Nektar Therapeutics : After the company's failed $3.
April 25, Nektar Therapeutics
April 25, Black Diamond Therapeutics : The company de-prioritized the development of a precision oncology drug, BDTX-189, in January of this year
April 25, Black Diamond Therapeutics
April 19, Imara : The company is refusing to develop its lead drug tovinontrine (IMR-687) and nuclear factor erythroid 2-related factor 2 activation for the treatment of sickle cell disease, beta-thalassemia, and heart failure with preserved ejection fraction.
April 19, Imara
On April 19, Finch Therapeutics: After the FDA clinically suspended the company's chronic hepatitis B program and microbiome drug CP101, the company announced a restructuring and layoffs of 20%
April 19, Finch Therapeutics:
On April 18, Magenta Therapeutics : Based on a restructuring, the company announced a 14% layoff and will focus on its targeted conditioning stem cell program and raising funds for sickle cell development
April 18, Magenta Therapeutics
April 13, ProQR : Ophthalmic RNA therapeutics-focused ProQR announced a strategic reorganization, including its chief scientific officer, after its Phase 2 drug, sepofarsen, failed to improve vision in patients with congenital eye diseases
April 13, ProQR
April 11, Stryker : As part of rolling layoffs at medical technology giant Stryker, a total of 88 jobs will be cut at the company's offices, more than two-thirds of which are production assistant positions, and the rest include automated feeders, cleaners, production Experts and a handful of team leaders
April 11, Stryker
April 9, PerkinElmer : The company will lay off 75 jobs on June 4 as contract with California for COVID-19 testing ends
April 9, PerkinElmer
April 8, Kaleido : Kaleido Therapeutics, which focuses on microbiome drug development, is preparing to lay off staff, including its chief executive, chief financial officer and chief strategy officer, after a dismal run of the past eight months
April 8, Kaleido
April 7, Akebia : Akebia plans to cut 42% or 47% of its workforce after a partial clinical hold and the FDA rejection of the company's lead drug candidate
April 7, Akebia
April 7, AbbVie : Starting next month, AbbVie will cut 178 jobs from its Stemcentrx division in San Francisco
April 7, AbbVie
April 5 , Sanofi : The French pharmaceutical company disclosed in its March 31 Worker Adjustment and Retraining Notice (WARN) notice that 25 workers will be "laid off" due to the closure of a plant in the state
April 5 , Sanofi April 5
April 5, Catalyst Biosciences : The company is at a crossroads in corporate development, with 70% of its workforce due to be laid off based on the need for a strategic restructuring of its R&D pipeline, according to the company's March 31 earnings report
April 5, Catalyst Biosciences
April 5, Bluebird Bio : Facing multiple R&D, regulatory and commercial setbacks, Bluebird Bio plans to lay off 30% of its workforce in order to maintain business development and cut costs, with a view to extending its cash flow to the first half of 2023
.
Novartis, April 4 : Novartis is undergoing a major internal restructuring with plans to combine its pharmaceutical and oncology businesses, confirming potential layoffs of thousands of jobs, with the company’s new structure fully in place and operational by the end of 2022
.
In March, 17 companies
In March, 17 companies March 31, Taysha Gene Therapies : The company announced a 35% layoff in March and narrowed its R&D focus on giant axonal neuropathy (GAN) and Rett syndrome in an effort to continue funding its gene therapy
.
31 March, NZ Pharma : NZ Pharma is in the honeymoon period for its first drug, which was approved less than a year ago
.
Problems with commercialization have led to the departure of its CEO and the layoff of 90 percent of its U.
S.
workforce
.
March 29, Bone Therapeutics : The company slashed top management, made major changes to its entire R&D pipeline, and focused on its "off-the-shelf" cell therapy platform - ALLOB
.
The program is currently conducting a Phase 2b trial in patients with high-risk tibial fractures and is evaluating patients with lumbar spine fusions
.
March 31, BridgeBio Pharma : BridgeBio is laying off an undisclosed number of jobs after disappointing Phase 3 results that shocked the company late last year
.
March 31, Silverback Therapeutics : The company announced a restructuring, reducing headcount by 27%, reducing operating expenses and extending its cash flow through 2026
.
The company also discontinued the SBT6050 and SBT6290 clinical oncology programs, focusing resources on the chronic hepatitis B virus programs SBT8230 and ImmunoTAC programs
.
March 30, Merck : The company has telegraphed its plans to cut back on the newly acquired unit just months after its $11.
5 billion deal with Acceleron Pharma
.
According to the Worker Adjustment and Retraining (WARN) Notice, Merck & Co.
is laying off a group of Acceleron employees in Cambridge, Massachusetts, affecting 143 employees, from May 31 to November 18
.
March 23, 2seventy bio : The company announced that it has taken significant steps to reduce overhead costs and simplify its operating model, including laying off 6% of its current workforce and an estimated annual cash outlay of approximately $30 million
.
March 23, Orion : The company will lay off 37 employees by announcing that it is downsizing its research and development division with plans to refocus its business on cancer and pain, leading to a halt in development for rare and neurodegenerative diseases
.
March 20, Zosano : Announcing a 31% layoff after the FDA refused to resubmit the company's migraine drug as the company explores strategic options, according to its March 17 earnings report
.
March 17, Athenex : To reduce operating costs by 50%, Athenex announced layoffs to focus R&D on cell therapies
.
March 16, Ovid Therapeutics : After a rough year, the company announced in its fourth-quarter earnings update a restructuring of its organization and a greater focus on epilepsy and epilepsy-related programs, and said it would cut down in the process 20% of employees, the measure helps extend Ovid's cash flow beyond 2024
.
March 16, Passage Bio : The company cut 13% of its workforce to cut operating costs and extend cash flow through the second quarter of 2024
.
And in March a partnership was formed with James Wilson, MD, and his lab at the University of Pennsylvania
.
Orphazyme , March 11 : Denmark's Orphazyme announced in March a second round of layoffs involving 50% of its global workforce in a court-mediated restructuring
.
Orphazyme recently closed its commercial operations in the US, UK and Germany
.
Importantly, the company plans to delist from the Nasdaq, possibly effective at the end of March
.
March 10, Adaptive Biotechnologies : Approximately 100 employees were laid off as a result of the company's business restructuring
.
The company will focus on two core medical areas focused on the immune system - minimal residual disease and immunotherapy, and will deprioritize any projects or initiatives that do not fit into the company's newly defined focus areas
.
March 9 , Gilead Sciences : Gilead Sciences announced that it would lay off 114 employees at the former headquarters of Immunology Medicine
.
March 4, Biogen : After a tumultuous nine months with a controversial Alzheimer's approval and a difficult launch (not to mention several clinical failures) of Aduhelm, Biogen's restructuring Affecting the work of many employees, the company has now begun sending layoff letters to some employees in the United States, the exact number of which is unknown
.
Epizyme , March 2 : The company reported earnings on March 1 that Epizyme is cutting 12% of its workforce and ending two clinical studies, including a mid-stage and early-stage combination trial of FDA-approved cancer treatment Tazverik, to reduce costs
.
In February, 5 companies
In February, 5 companies Feb.
28, Gemini Therapeutics : The company's president and CEO left Gemini in late February, along with 24 employees, as the company realigned its strategic direction and shifted priorities to its preclinical pipeline
.
The company, which had already restructured in October to focus on late-stage plans for its eye drug, made another strategic shift in less than six months, this time cutting 80% of its workforce
.
Feb.
17, Yumanity : After the FDA partially suspended a multi-dose clinical trial of YTX-7739 for Parkinson's disease, the company announced it would lay off 60% of its workforce by April while the company will focus on neurodegeneration STD Technology Finds Buyers
.
Feb.
12 , Metacrine : Metacrine halved its workforce after its NASH failure last year and ended a preclinical effort for fatty liver disease after the NASH failure
.
The company said the massive layoffs and pipeline downsizing are aimed at improving the company's focus on inflammatory bowel disease, particularly ulcerative colitis, in a phase 2 trial that is scheduled to begin in the first half of this year after FDA approval
.
Feb.
8 , Biosplice : The $12 billion Biosplice company cut 41 jobs in February and eliminated a male-pattern hair loss drug from its pipeline
.
Unity Biotechnology, Feb.
4 : The anti-aging biotech will cut another 50% of its workforce in early February and re-prioritize its pipeline to focus on ophthalmology research, with the expectation of extending cash flow into the first quarter of 2023
.
In January, 8 companies
In January, 8 companies Jan.
31 , Gamida Cell : The company is submitting an application to the FDA for the blood cancer therapy omidubicel, which is being developed as an off-the-shelf bone marrow stem cell transplant for the treatment of blood cancers
.
To bring the drug to market, the company is seeking strategic partners for commercialization in the U.
S.
or globally, and needs to reduce headcount by 10%
.
Jan.
29 , Kaleido Biosciences : The company confirmed the layoffs in an emailed statement as it halted work on a planned Phase 2 clinical trial in chronic obstructive pulmonary disease and terminated its agreement with the COPD Foundation
.
January 20 , Zymeworks : New CEO Kenneth Galbraith announced after taking office that he would cut half of the senior leadership and lay off 25% of the workforce, including chief scientific officer and executive vice president of early development, chief people officer and chief commercial officer
.
Jan.
21 , Acutus Medical : Despite doubling revenue in 2021, the company plans to cut costs and lay off workers to cut tens of millions of dollars in annual operating expenses
.
It did not say how many jobs it has cut
.
But the government and affected employees must be notified of layoffs under the Worker Adjustment and Retraining Notification (WARN) Act, which requires employers to give workers 60 days' notice before laying off at least 50 people
.
Jan.
31 , Leo Pharma : The company announced some major restructuring, affecting about 68 employees, but the restructuring could eventually affect 1,000 of the company's jobs over the next two years
.
Currently, the company is closing its regenerative medicine innovation centers and technology centers in Asia and Boston
.
Jan.
12 , Daiichi Sankyo : The Japanese pharmaceutical company announced it would close its 60-person Plexxiko R&D facility in California
.
The company, which received $805 million upfront 10 years ago, has opted to close in an effort to free up funds for the development of its ADC drug pipeline
.
Jan.
12 , BeyondSpring : The company laid off 35% of its U.
S.
workforce Jan.
12 after the FDA rejected its chemotherapy-induced neutropenia drug Plinabulin
.
Jan.
5 , Spectrum Therapeutics : The company announced 30% layoffs on Jan.
5 to save cash flow and focus on mid- to late-stage cancer drugs
.
The move follows the FDA rejection of its neutropenic drug candidate Rolontis in August 2021
.
English link: https:// href="https://" target="_blank">https://
